| Budget Amount *help |
¥199,810,000 (Direct Cost: ¥153,700,000、Indirect Cost: ¥46,110,000)
Fiscal Year 2023: ¥36,530,000 (Direct Cost: ¥28,100,000、Indirect Cost: ¥8,430,000)
Fiscal Year 2022: ¥38,220,000 (Direct Cost: ¥29,400,000、Indirect Cost: ¥8,820,000)
Fiscal Year 2021: ¥41,600,000 (Direct Cost: ¥32,000,000、Indirect Cost: ¥9,600,000)
Fiscal Year 2020: ¥42,640,000 (Direct Cost: ¥32,800,000、Indirect Cost: ¥9,840,000)
Fiscal Year 2019: ¥40,820,000 (Direct Cost: ¥31,400,000、Indirect Cost: ¥9,420,000)
|
|---|
| Outline of Final Research Achievements |
Combining our newly established method for evaluating neuropathic allodynia by selective stimulation of primary afferent Aβ fibers (touch-sensing fibers) with a method for regulating cell subset-specific functions using viral vectors, we identified several neuronal and glial subsets important for neuropathic allodynia. In particular, dysfunction of the NPY+ neuronal subset after nerve injury was found to play a central role in the development of neuropathic allodynia. In addition, we found that signaling from glial cells is responsible for the dysfunction of NPY+ neurons. Furthermore, we also showed that an analgesic effect of the clinically approved drug duloxetine requires the activation of NPY+ neurons, and we identified compounds that can enhance the function of NPY+ neurons.
|
